<DOC>
	<DOCNO>NCT00885157</DOCNO>
	<brief_summary>The purpose study investigate use fourth fractional booster dose sanofi pasteur 's IMOVAX Polio inject intradermally ( use Mantoux technique ) booster dose 15 18 month age , term immunogenicity safety . Objectives : - To describe group immunogenicity IMOVAX Polio administer intradermally intramuscularly , one month booster dose give 15-18 month age toddler previously prim three dos IMOVAX Polio vaccine IPV25 study . - To describe group safety booster dose IMOVAX Polio vaccine administer intradermally intramuscularly .</brief_summary>
	<brief_title>Immunogenicity Safety Fractional Booster Dose IPV Intradermally Versus Full Dose Intramuscularly</brief_title>
	<detailed_description />
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Aged 15 18 month day inclusion Informed consent form sign parent ( ) legally acceptable representative Subjects parent/guardian able attend schedule visit comply trial procedure Child complete visit IPV25 study ( NCT00604058 ) , include threedose primary vaccination series study vaccine ( IMOVAX Polio ) , use route administration designate randomization . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion , opinion investigator Receipt blood bloodderived product since birth might interfere assessment immune response Receipt vaccine 4 week precede trial vaccination Planned receipt vaccine present trial period Known personal maternal Human Immunodeficiency Virus ( HIV ) , Hepatitis B antigen Hepatitis C seropositivity History seizures History poliomyelitis infection ( confirm either clinically , serologically microbiologically ) Previous fourth dose vaccination poliomyelitis disease either trial vaccine another vaccine Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate IM injection Febrile illness ( temperature ≥38.0 °C ) moderate severe acute illness/infection day vaccination , accord investigator judgment .</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Poliomyelitis</keyword>
	<keyword>intradermal</keyword>
</DOC>